Alaunos Therapeutics, Inc (TCRT) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Alaunos Therapeutics, Inc stock $0.75, price $1.59, that is 52.8% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Alaunos Therapeutics, Inc
TCRT · USFar too expensive (fair value 53% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.74 – $553.50 · fair‑value band $0.56 – $0.94 · the $1.59 price screens above the $0.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Alaunos Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders.
Show moreShow less
It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Stock analysis
Alaunos Therapeutics, Inc (TCRT) currently trades at $1.59, while our estimate is $0.75, 53% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.56 (bear) to $0.94 (bull), the price of $1.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Alaunos Therapeutics, Inc reported revenue of $5.0K in FY2025 versus $398K in FY2021, a compound −66.5%/yr. Reported net income was −$4.2M in FY2025.
Key figures
Market cap $6.8M Micro · EPS (TTM) $-1.76 · Return on equity −186% · Return on assets (EBIT) −174% (5-year average) · Operating margin −135,233% · Revenue (TTM) $3.0K · Revenue growth (YoY) −25.0% · Free cash flow −$3.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 115% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −53%, TCRT screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 19, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Alaunos Therapeutics, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 852 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $923.34 | $1,275.02 | +38% | vs TCRT |
| Vertex Pharmaceuticals Incorporated VRTX | $520.66 | $587.62 | +13% | vs TCRT |
| Samsung Biologics Co 207940 | ₩1,355,000 | ₩1,512,500 | +12% | vs TCRT |
| argenx SE ARGX | $942.04 | $908.40 | −4% | vs TCRT |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs TCRT |
| BeOne Medicines AG 6160 | HK$230.80 | HK$152.92 | −34% | vs TCRT |
| Moderna, Inc MRNA | $199.33 | $122.98 | −38% | vs TCRT |
| Revolution Medicines, Inc RVMD | $159.43 | $83.12 | −48% | vs TCRT |
| Celltrion, Inc 068270 | ₩213,000 | ₩74,574 | −65% | vs TCRT |
| Royalty Pharma plc RPRX | $67.72 | $19.01 | −72% | vs TCRT |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Alaunos Therapeutics, Inc (TCRT) overvalued or undervalued?
What is the fair value of TCRT?
What is the quality score of TCRT?
What is the price target for Alaunos Therapeutics, Inc (TCRT)?
What is the Alaunos Therapeutics, Inc stock forecast for 2026?
What is the revenue of Alaunos Therapeutics, Inc (TCRT)?
What is the intrinsic value of Alaunos Therapeutics, Inc (TCRT)?
Is Alaunos Therapeutics, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of TCRT?
How much is Alaunos Therapeutics, Inc worth?
What do the bullish and bearish scenarios say about TCRT?
What is the PEG ratio of TCRT?
How solid is the balance sheet of Alaunos Therapeutics, Inc (TCRT)?
How far is TCRT from its 52-week high?
Which stocks are comparable to Alaunos Therapeutics, Inc?
Is Alaunos Therapeutics, Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Alaunos Therapeutics, Inc (TCRT)?
What should I pay attention to with Alaunos Therapeutics, Inc right now?
Key figures of Alaunos Therapeutics, Inc
How large is the market capitalisation of Alaunos Therapeutics, Inc (TCRT)?
What are the earnings per share of Alaunos Therapeutics, Inc (TCRT)?
What is the return on equity of Alaunos Therapeutics, Inc (TCRT)?
What is the EBIT return on assets of Alaunos Therapeutics, Inc (TCRT)?
What is the operating margin of Alaunos Therapeutics, Inc (TCRT)?
How fast is revenue growing at Alaunos Therapeutics, Inc (TCRT)?
How much free cash flow does Alaunos Therapeutics, Inc (TCRT) generate?
How much net cash does Alaunos Therapeutics, Inc (TCRT) hold?
Watch Alaunos Therapeutics, Inc in the live analysis
One click puts Alaunos Therapeutics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.